Physician profile
Nadeem U Haque
NPI 1538121926
$5,162.97
in general payments reported to CMS, 2019-2025
41 companies · $1,039 in 2025
The $1,039 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $436 · 2020: $417 · 2021: $995 · 2022: $769 · 2023: $550 · 2024: $957 · 2025: $1,039.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,545.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,183.96 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $415.85 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $317.33 | 2019-2025 | Krystexxa |
| Novo Nordisk INC | $314.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Ironwood Pharmaceuticals, INC | $289.71 | 2020-2024 | Linzess |
| Viatris Specialty LLC | $279.06 | 2025 | Yupelri |
| Abbvie INC. | $263.22 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $243.21 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $206.06 | 2019-2024 | Yupelri |
| Allergan, INC. | $161.33 | 2019-2020 | |
| Imperative Care, INC | $134.29 | 2025 | Zoom 88-T Large Distal Platform |
| Lilly USA, LLC | $127.47 | 2019-2025 | Jardiance |
| Ardelyx, INC. | $110.45 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $100.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.04 | 2019 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.